On World Diabetes Day, Sanofi is celebrating an approval recommendation in the EU for Teizeild, a first-in-class drug ...

MSD has announced a takeover deal for Cidara Therapeutics, an infectious disease specialist currently focused on developing a ...

In a statement, Avadel acknowledged that it had received the Lundbeck bid and that its board of directors had "determined in ...

The growth of the stronger product – which now accounts for more than a quarter of Eylea sales – allowed Bayer to predict ...

Kura Oncology has claimed FDA approval for oral menin inhibitor Komzifti for a form of acute myeloid leukaemia (AML), making ...

Alkermes already has positive results for alixorexton in NT1 from the phase 2 Vibrance-1, while Takeda is developing another ...

At ESMO 2025 in Berlin, pharmaphorum spoke with Tadaaki Taniguchi, Chief Research & Development Officer at Astellas, about ...

The study of GanLum (KLU156) – a combination of novel drug ganaplacide with established antimalarial lumefantrine – showed ...

The $6.7 billion merger brought together two companies that had been forced to file for bankruptcy protection due to opioid ...

This World Diabetes Day, Sanofi UK and DigiBete are hosting a pop-up event in Leeds today and tomorrow, 14th & 15th November, ...

Roche has built the evidence for its oral BTK inhibitor fenebrutinib in multiple sclerosis (MS) with two phase 3 readouts ...

Eisai has already reached settlement agreements with two other companies seeking to market Lenvima generics in the US – Sun ...